{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:52:46Z","timestamp":1793321566461,"version":"4.5.0"},"reference-count":130,"publisher":"Oxford University Press (OUP)","issue":"31","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite existing treatments, patients with heart failure and chronic kidney disease (CKD) remain at high risk for adverse outcomes and progression to end-stage disease. Steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone reduce mortality but remain under-prescribed due to the perceived risk of hyperkalaemia and hormonal side effects. The discovery of non-steroidal MRAs represents a major new dimension in cardiorenal disease therapy. Non-steroidal MRAs have high affinity and specificity for the mineralocorticoid receptor (MR) and differ from both steroidal agents and each other with respect to important physiochemical, pharmacodynamic, and pharmacokinetic parameters. Similar to their steroidal counterparts, they have beneficial anti-inflammatory, anti-remodelling, and anti-fibrotic properties in the kidneys, heart, and vasculature. There are several non-steroidal MRAs under development and clinical assessment; of these, only esaxerenone and finerenone are approved for treatment globally. In Japan, esaxerenone is approved for essential hypertension and has been studied in diabetic nephropathy. Compared with steroidal MRAs, finerenone more potently inhibits MR co-regulator recruitment and fibrosis and distributes more evenly between the heart and kidneys. The landmark Phase III trials FIGARO-DKD and FIDELIO-DKD demonstrated that finerenone-reduced major kidney and cardiovascular events on top of maximally tolerated renin\u2013angiotensin\u2013aldosterone system inhibition in patients with CKD associated with Type 2 diabetes. Non-steroidal MRAs are currently under evaluation in heart failure and for synergistic treatment with sodium\u2013glucose contransporter 2 inhibitors. These ground-breaking agents could become an important therapy across the spectrum of cardiorenal disease.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehac299","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T12:20:23Z","timestamp":1655468423000},"page":"2931-2945","source":"Crossref","is-referenced-by-count":81,"title":["Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease"],"prefix":"10.1093","volume":"43","author":[{"given":"Arjun K","family":"Pandey","sequence":"first","affiliation":[{"name":"Michael G. DeGroote School of Medicine, McMaster University , Hamilton, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6967-5685","authenticated-orcid":false,"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medicine Solna, Karolinska Institute & Karolinska University Hospital , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-634X","authenticated-orcid":false,"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Cardiology, University Hospital Aachen, RWTH Aachen University , Aachen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Rotstein","sequence":"additional","affiliation":[{"name":"Department of Surgery, St Michael's Hospital, University of Toronto , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan School of Medicine , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi School of Medicine , Jackson, MS , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-8533","authenticated-orcid":false,"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St Michael's Hospital, University of Toronto , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"2022081704472122700_ehac299-B1","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"2022081704472122700_ehac299-B2","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2022081704472122700_ehac299-B3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"2022081704472122700_ehac299-B4","doi-asserted-by":"crossref","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders\u2212 New perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"key":"2022081704472122700_ehac299-B5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2022081704472122700_ehac299-B6","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"2022081704472122700_ehac299-B7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/edrv-17-6-587","article-title":"Interaction of steroid hormone receptors with the transcription initiation complex","volume":"17","author":"Beato","year":"1996","journal-title":"Endocr Rev"},{"key":"2022081704472122700_ehac299-B8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cphy.c130044","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"key":"2022081704472122700_ehac299-B9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2022081704472122700_ehac299-B10","article-title":"Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor","author":"Clarisse","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2022081704472122700_ehac299-B11","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","author":"Kintscher","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2022081704472122700_ehac299-B12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0303-7207(00)00429-9","article-title":"Enzyme-mediated protection of the mineralocorticoid receptor against progesterone in the human kidney","volume":"171","author":"Quinkler","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"2022081704472122700_ehac299-B13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41371-020-0360-2","article-title":"Structural determinants of activation of the mineralocorticoid receptor: an evolutionary perspective","volume":"35","author":"Fuller","year":"2021","journal-title":"J Hum Hypertens"},{"key":"2022081704472122700_ehac299-B14","first-page":"129","volume-title":"Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine","author":"Funder","year":"2013"},{"key":"2022081704472122700_ehac299-B15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/B978-0-12-803247-3.00029-5","volume-title":"Textbook of Nephro-Endocrinology","author":"Gomez-Sanchez","year":"2018"},{"key":"2022081704472122700_ehac299-B16","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1096\/fj.13-242479","article-title":"Identification and characterization of a ligand-selective mineralocorticoid receptor coactivator","volume":"28","author":"Rogerson","year":"2014","journal-title":"FASEB J"},{"key":"2022081704472122700_ehac299-B17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-11-0372","article-title":"Mechanisms of ligand specificity of the mineralocorticoid receptor","volume":"213","author":"Fuller","year":"2011","journal-title":"J Endocrinol"},{"key":"2022081704472122700_ehac299-B18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11906-012-0297-0","article-title":"The ubiquitous mineralocorticoid receptor: clinical implications","volume":"14","author":"Hawkins","year":"2012","journal-title":"Curr Hypertens Rep"},{"key":"2022081704472122700_ehac299-B19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2022081704472122700_ehac299-B20","doi-asserted-by":"crossref","first-page":"38911","DOI":"10.1074\/jbc.M103984200","article-title":"Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor","volume":"276","author":"Le Menuet","year":"2001","journal-title":"J Biol Chem"},{"key":"2022081704472122700_ehac299-B21","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias","volume":"111","author":"Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"key":"2022081704472122700_ehac299-B22","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1681\/ASN.2006090975","article-title":"Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor","volume":"18","author":"Ronzaud","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2022081704472122700_ehac299-B23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00424-015-1785-2","article-title":"Adult nephron-specific MR-deficient mice develop a severe renal PHA-1 phenotype","volume":"468","author":"Canonica","year":"2016","journal-title":"Pflugers Arch"},{"key":"2022081704472122700_ehac299-B24","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1681\/ASN.2015070815","article-title":"Direct and indirect mineralocorticoid effects determine distal salt transport","volume":"27","author":"Terker","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2022081704472122700_ehac299-B25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"2022081704472122700_ehac299-B26","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1161\/HYPERTENSIONAHA.112.203158","article-title":"Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone\/salt-mediated inflammation and cardiac fibrosis","volume":"60","author":"Rickard","year":"2012","journal-title":"Hypertension"},{"key":"2022081704472122700_ehac299-B27","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/HYPERTENSIONAHA.115.05981","article-title":"Cardiomyocyte mineralocorticoid receptor activation impairs acute cardiac functional recovery after ischemic insult","volume":"66","author":"Bienvenu","year":"2015","journal-title":"Hypertension"},{"key":"2022081704472122700_ehac299-B28","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1681\/ASN.2012111094","article-title":"Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease","volume":"25","author":"Huang","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022081704472122700_ehac299-B29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"Rickard","year":"2009","journal-title":"Hypertension"},{"key":"2022081704472122700_ehac299-B30","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J Clin Invest"},{"key":"2022081704472122700_ehac299-B31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1161\/STROKEAHA.110.598441","article-title":"Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia","volume":"42","author":"Frieler","year":"2011","journal-title":"Stroke"},{"key":"2022081704472122700_ehac299-B32","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/en.2016-1040","article-title":"Cardiac tissue injury and remodeling is dependent upon MR regulation of activation pathways in cardiac tissue macrophages","volume":"157","author":"Shen","year":"2016","journal-title":"Endocrinology"},{"key":"2022081704472122700_ehac299-B33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1161\/HYPERTENSIONAHA.118.12162","article-title":"Macrophage mineralocorticoid receptor is a pleiotropic modulator of myocardial infarct healing","volume":"73","author":"Fraccarollo","year":"2019","journal-title":"Hypertension"},{"key":"2022081704472122700_ehac299-B34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11906-016-0649-2","article-title":"Finerenone: a new mineralocorticoid receptor antagonist without hyperkalemia: an opportunity in patients with CKD?","volume":"18","author":"Haller","year":"2016","journal-title":"C Hypertens Rep"},{"key":"2022081704472122700_ehac299-B35","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/JME-15-0318","article-title":"Mineralocorticoid regulation of cell function: the role of rapid signalling and gene transcription pathways","volume":"58","author":"Ong","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"2022081704472122700_ehac299-B36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.kisu.2021.11.001","article-title":"Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms","volume":"12","author":"Bauersachs","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2022081704472122700_ehac299-B37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2022081704472122700_ehac299-B38","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2022081704472122700_ehac299-B39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2022081704472122700_ehac299-B40","article-title":"2021 Dec 20. Identifier NCT02901184, Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (SPIRRIT); 2021 Jun 22. Available from","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B41","article-title":"2021 Dec 20. Identifier NCT04727073, Spironolactone In The Treatment of Heart Failure (SPIRIT-HF); 2021 Jan 29. Available from","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B42","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/ejhf.1716","article-title":"Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial","volume":"22","author":"Pellicori","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022081704472122700_ehac299-B43","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/hrt.2010.215459","article-title":"Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction","volume":"97","author":"Kasama","year":"2011","journal-title":"Heart"},{"key":"2022081704472122700_ehac299-B44","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","article-title":"Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"2022081704472122700_ehac299-B45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1753944715591448","article-title":"Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients","volume":"9","author":"Feniman-De-Stefano","year":"2015","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2022081704472122700_ehac299-B46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/jhh.2014.83","article-title":"Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy","volume":"29","author":"Gupta","year":"2015","journal-title":"J Hum Hypertens"},{"key":"2022081704472122700_ehac299-B47","doi-asserted-by":"crossref","first-page":"e019434","DOI":"10.1161\/JAHA.120.019434","article-title":"Spironolactone reduces aortic stiffness in patients with resistant hypertension independent of blood pressure change","volume":"10","author":"Aryal","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2022081704472122700_ehac299-B48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2022081704472122700_ehac299-B49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.phrs.2018.11.037","article-title":"Canrenone on cardiovascular mortality in congestive heart failure: canrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study","volume":"141","author":"Derosa","year":"2019","journal-title":"Pharmacol Res"},{"key":"2022081704472122700_ehac299-B50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2022081704472122700_ehac299-B51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"2022081704472122700_ehac299-B52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jama.1973.03220010068036","article-title":"Gynecomastia and impotence complications of spironolactone therapy","volume":"223","author":"Greenblatt","year":"1973","journal-title":"JAMA"},{"key":"2022081704472122700_ehac299-B53","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-87-4-398","article-title":"Pathophysiology of spironolactone-induced gynecomastia","volume":"87","author":"Rose","year":"1977","journal-title":"Ann Intern Med"},{"key":"2022081704472122700_ehac299-B54","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"2022081704472122700_ehac299-B55","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/ncpendmet0676","article-title":"Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist","volume":"4","author":"McManus","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2022081704472122700_ehac299-B56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"2022081704472122700_ehac299-B57","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","article-title":"Eplerenone: cardiovascular protection","volume":"107","author":"Brown","year":"2003","journal-title":"Circulation"},{"key":"2022081704472122700_ehac299-B58","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2022081704472122700_ehac299-B59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2022081704472122700_ehac299-B60","first-page":"217","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2022081704472122700_ehac299-B61","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022081704472122700_ehac299-B62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2019.02.005","article-title":"Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: the MINIMIZE STEMI trial","volume":"211","author":"Bulluck","year":"2019","journal-title":"Am Heart J"},{"key":"2022081704472122700_ehac299-B63","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"},{"key":"2022081704472122700_ehac299-B64","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2022081704472122700_ehac299-B65","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022081704472122700_ehac299-B66","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s11255-016-1319-7","article-title":"Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis","volume":"48","author":"Lu","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"2022081704472122700_ehac299-B67","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2022081704472122700_ehac299-B68","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"2022081704472122700_ehac299-B69","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int"},{"key":"2022081704472122700_ehac299-B70","article-title":"2021 Dec 20. Identifier NCT03020303, Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE); 2020 Oct 29","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B71","article-title":"2021 Dec 20. Identifier NCT01848639, ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST); 2020 Oct 28","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B72","article-title":"2021 Dec 20. Identifier NCT03048825, Colchicine and Spironolactone in Patients With MI\/SYNERGY Stent Registry (CLEAR SYNERGY); 2020 Sept 16","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ahj.2019.04.023","article-title":"Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: rationale and design of the ALDOCURE trial","volume":"214","author":"Alexandre","year":"2019","journal-title":"Am Heart J"},{"key":"2022081704472122700_ehac299-B74","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.ejheart.2007.09.008","article-title":"Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey","volume":"9","author":"De Groote","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2022081704472122700_ehac299-B75","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022081704472122700_ehac299-B76","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cardfail.2006.01.003","article-title":"Appropriateness of spironolactone prescribing in heart failure patients: a population-based study","volume":"12","author":"Ko","year":"2006","journal-title":"J Cardiac Fail"},{"key":"2022081704472122700_ehac299-B77","doi-asserted-by":"crossref","first-page":"c1768","DOI":"10.1136\/bmj.c1768","article-title":"Spironolactone use and renal toxicity: population based longitudinal analysis","volume":"340","author":"Wei","year":"2010","journal-title":"BMJ"},{"key":"2022081704472122700_ehac299-B78","volume-title":"Aldosterone-Mineralocorticoid Receptor\u2014Cell Biology to Translational Medicine","author":"de Vega","year":"2019"},{"key":"2022081704472122700_ehac299-B79","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2013.00115","article-title":"PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy","volume":"4","author":"Orena","year":"2013","journal-title":"Front Pharmacol"},{"key":"2022081704472122700_ehac299-B80","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/jcph.865","article-title":"Population pharmacokinetics of LY2623091 in patients with hypertension and chronic kidney disease","volume":"57","author":"Wang","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2022081704472122700_ehac299-B81","doi-asserted-by":"crossref","first-page":"604928","DOI":"10.3389\/fphar.2021.604928","article-title":"The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria and has improved therapeutic index compared with eplerenone in a rat model with mineralocorticoid-induced renal injury","volume":"12","author":"Jaisser","year":"2021","journal-title":"Front Pharmacol"},{"key":"2022081704472122700_ehac299-B82","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2022081704472122700_ehac299-B83","article-title":"2021 Dec 20. Identifier NCT04968184, Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe CKD (Clarion-CKD); 2022 Jan 3","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B84","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose\u2013response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2022081704472122700_ehac299-B85","doi-asserted-by":"crossref","first-page":"e0193380","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"key":"2022081704472122700_ehac299-B86","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bcp.13562","article-title":"Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator","volume":"84","author":"Erlandsson","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2022081704472122700_ehac299-B87","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cts.12705","article-title":"Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: a phase I multiple ascending dose study","volume":"13","author":"Whittaker","year":"2020","journal-title":"Clin Transl Sci"},{"key":"2022081704472122700_ehac299-B88","doi-asserted-by":"crossref","DOI":"10.1177\/1470320319827449","article-title":"The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone","volume":"20","author":"Bamberg","year":"2019","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2022081704472122700_ehac299-B89","article-title":"2021 Dec 20. Identifier NCT04595370, Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease; 2021 Nov 18","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B90","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: first global approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"2022081704472122700_ehac299-B91","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"2022081704472122700_ehac299-B92","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.3390\/ijms22042069","article-title":"Cardioprotective effects of a nonsteroidal mineralocorticoid receptor blocker, esaxerenone, in Dahl salt-sensitive hypertensive rats","volume":"22","author":"Rahman","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2022081704472122700_ehac299-B93","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","article-title":"Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice","volume":"42","author":"Bhuiyan","year":"2019","journal-title":"Hypertens Res"},{"key":"2022081704472122700_ehac299-B94","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022081704472122700_ehac299-B95","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"2022081704472122700_ehac299-B96","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/ajh\/hpaa155","article-title":"Effect of the nonsteroidal mineralocorticoid receptor blocker, esaxerenone, on nocturnal hypertension: a post hoc analysis of the ESAX-HTN study","volume":"34","author":"Kario","year":"2021","journal-title":"Am J Hypertens"},{"key":"2022081704472122700_ehac299-B97","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","article-title":"Finerenone: first approval","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"key":"2022081704472122700_ehac299-B98","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"2022081704472122700_ehac299-B99","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2022081704472122700_ehac299-B100","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"2022081704472122700_ehac299-B101","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"2022081704472122700_ehac299-B102","doi-asserted-by":"crossref","first-page":"e21314","DOI":"10.1096\/fj.202002043RR","article-title":"Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells","volume":"35","author":"Le Billan","year":"2021","journal-title":"FASEB J"},{"key":"2022081704472122700_ehac299-B103","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","article-title":"Mineralocorticoid receptor antagonists\u2014pharmacodynamics and pharmacokinetic differences","volume":"27","author":"Yang","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"2022081704472122700_ehac299-B104","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2022081704472122700_ehac299-B105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022081704472122700_ehac299-B106","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022081704472122700_ehac299-B107","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"2022081704472122700_ehac299-B108","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/dom.13393","article-title":"Short-and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction","volume":"20","author":"Lachaux","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022081704472122700_ehac299-B109","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front Pharmacol"},{"key":"2022081704472122700_ehac299-B110","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"2022081704472122700_ehac299-B111","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/eurheartj\/ehw155","article-title":"Finerenone in heart failure: walking a fine line","volume":"37","author":"Naegele","year":"2016","journal-title":"Eur Heart J"},{"key":"2022081704472122700_ehac299-B112","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2022081704472122700_ehac299-B113","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2022081704472122700_ehac299-B114","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2022081704472122700_ehac299-B115","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2022081704472122700_ehac299-B116","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2022081704472122700_ehac299-B117","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with CKD and T2D with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2022081704472122700_ehac299-B118","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2022081704472122700_ehac299-B119","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022081704472122700_ehac299-B120","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/dc21-1944","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2022081704472122700_ehac299-B121","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and Type 2 diabetes with or without sodium-glucose Cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2022081704472122700_ehac299-B122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2022081704472122700_ehac299-B123","doi-asserted-by":"crossref","first-page":"e025079","DOI":"10.1161\/JAHA.121.025079","article-title":"Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone","author":"Chiu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2022081704472122700_ehac299-B124","article-title":"2021 Dec 20. Identifier NCT05047263, A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD); 2021 Dec 1","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B125","article-title":"2021 Dec 20. Identifier NCT04435626, Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF); 2021 Dec 9","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B126","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur Heart J"},{"key":"2022081704472122700_ehac299-B127","article-title":"2021 Dec 20. Identifier NCT05254002, A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE); 2022 Mar 23","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B128","article-title":"2021 Dec 20. Identifier NCT04142788, RELieving Increasing oEdema Due to Heart Failure (RELIEHF); 2021 Dec 16","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B129","article-title":"2021 Dec 20. Identifier NCT03888066, Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) (DIAMOND); 2021 Oct 21","author":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)"},{"key":"2022081704472122700_ehac299-B130","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ejhf.2386","article-title":"Patiromer for the management of hyperkalaemia in patients receiving renin\u2013angiotensin\u2013aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/31\/2931\/45449378\/ehac299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/31\/2931\/45449378\/ehac299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:48:52Z","timestamp":1660697332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/31\/2931\/6609642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":130,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2022,6,17]]},"published-print":{"date-parts":[[2022,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac299","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,14]]},"published":{"date-parts":[[2022,6,17]]}}}